BioHarvest Sciences Inc. (BHST) Stock Forecast
BHST analyst forecast
as of October 18, 2026- Analyst consensus
- Strong buy 4.75 / 5 from 4 analysts
- Price target
- $10.50 average of analyst targets
- Upside to target
- +467.6% from the latest close
- Next earnings
- November 12, 2026 EPS estimate $-0.16
- 52-week range
- $1.45 – $11.90
BHST analyst ratings
4 analystsNumber of analysts at each rating.
BHST price target
The average of analyst 12-month price targets compared with the latest close and the 52-week range.
BHST earnings per share estimates
| Period | Average | Low | High | Year ago | Growth | Analysts |
|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$0.14 | −$0.18 | −$0.10 | −$0.14 | +1.8% | 4 |
| Current fiscal year (2026) | −$0.53 | −$0.59 | −$0.45 | −$0.60 | +12.1% | 4 |
| Next fiscal year (2027) | −$0.34 | −$0.43 | −$0.25 | −$0.53 | +36.5% | 4 |
Consensus EPS estimates; growth compares the average estimate with the year-ago EPS.
BHST revenue estimates
| Period | Average | Low | High | Growth | Analysts |
|---|---|---|---|---|---|
| Current quarter (Sep '26) | $9.3M | $8.8M | $10.4M | +2.6% | 4 |
| Current fiscal year (2026) | $37.4M | $37.0M | $38.0M | +8.4% | 4 |
| Next fiscal year (2027) | $49.6M | $46.0M | $52.8M | +32.5% | 4 |
BHST EPS: reported and forecast
Fiscal years; "E" marks estimates, the line shows the range from the lowest to the highest estimate.
BHST revenue: reported and forecast
BHST EPS estimate revisions
| Period | 90 days ago | 60 days ago | 30 days ago | 7 days ago | Now | Change (90 d) | Revisions (30 d) |
|---|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$0.06 | −$0.10 | −$0.10 | −$0.10 | −$0.14 | +120.0% | 0 up · 3 down |
| Current fiscal year (2026) | −$0.33 | −$0.41 | −$0.41 | −$0.41 | −$0.53 | +62.3% | 0 up · 4 down |
| Next fiscal year (2027) | −$0.09 | −$0.17 | −$0.17 | −$0.17 | −$0.34 | +294.1% | 1 up · 3 down |
How the consensus EPS estimate changed over the last 90 days, and how many analysts raised or lowered it in the last 30 days.
BHST earnings surprises
Reported EPS vs the consensus estimate for the last 12 quarters; BHST beat in 4 of 9.
What analysts expect from BHST
4 analysts cover BioHarvest Sciences; their consensus rating is strong buy (4.75 on a 1–5 scale, where 5 is a strong buy). The average price target is $10.50, 467.6% above the latest close of $1.85. Analysts expect earnings of −$0.53 per share for 2026, +12.1% from a year earlier. For 2027 the average estimate is −$0.34 per share on revenue of $49.6 million. BioHarvest Sciences beat the EPS estimate in 4 of the last 9 quarters.
Related: BHST income statement, BHST key metrics, BHST chart. See the BHST stock overview for the latest quote and news.
BHST forecast FAQ
What is BioHarvest Sciences's price target?
The average analyst price target for BioHarvest Sciences is $10.50, 467.6% above the latest close of $1.85.
Is BioHarvest Sciences a buy, hold or sell?
Of 4 analysts covering BioHarvest Sciences, 3 rate it a strong buy, 1 a buy, 0 a hold, 0 a sell and 0 a strong sell, a consensus of strong buy. Ratings are opinions, not a recommendation from Quotelinks.
What is BioHarvest Sciences's EPS forecast?
Analysts forecast −$0.53 per share for 2026 (range −$0.59 to −$0.45); for 2027 the estimate is −$0.34.
What is BioHarvest Sciences's revenue forecast?
The average revenue estimate for 2026 is $37.4 million, growth of 8.4%; for 2027 it is $49.6 million.
When does BioHarvest Sciences report earnings?
BioHarvest Sciences is expected to report results for the quarter ending September 30, 2026 on November 12, 2026 before the market opens; the EPS estimate is $-0.16.
Does BioHarvest Sciences usually beat earnings estimates?
BioHarvest Sciences reported EPS at or above the analyst estimate in 4 of the last 9 quarters.